EyeGene Inc.
Financials
Valuation Metrics
EyeGene Inc.'s Market Cap is ₩674B. At end of 2025 it was ₩752B. Ranked #1524 of 2,436 in KR market (top 63%), #882 of 1,649 on KOSDAQ (top 53%), #170 of 234 in Pharmaceuticals, Biotechnology & Life Sciences (top 73%) by Market Cap.
Investment Metrics(as of 2026-08-04)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 67.44B KRW | KR#1,524/2,436 Sec#170/234 |
| Revenue | 4.02B KRW | KR#2,360/2,436 Sec#202/234 |
| Net Income | -19.65B KRW | KR—/2,436 Sec—/234 |
| Total Assets | 64.70B KRW | KR#2,037/2,436 Sec#173/234 |
| Net Assets | 50.92B KRW | KR#1,866/2,436 Sec#161/234 |
| Employees | 50 | KR#2,027/2,436 Sec#184/234 |
| Value | ||
| P/B | 1.32x | KR#1,711/2,436 Sec#120/234 |
| P/S | 16.77x | KR#2,320/2,436 Sec#179/234 |
| FCF Yield | -9.02% | KR—/2,436 Sec—/234 |
| Profitability | ||
| ROE | -38.58% | KR#2,224/2,436 Sec#186/234 |
| ROA | -30.36% | KR#2,305/2,436 Sec#201/234 |
| Op. Margin | -270.73% | KR#2,354/2,436 Sec#195/234 |
| Revenue Growth | 55.55% | KR#264/2,436 Sec#28/234 |
| Financial Health | ||
| Debt Ratio | 27.06% | KR#82/2,436 Sec#9/234 |
| Total Debt | 0 KRW | KR—/2,436 Sec—/234 |
| FCF | -6.08B KRW | KR#1,557/2,436 Sec#124/234 |
| Cash | 7.16B KRW | KR#1,850/2,436 Sec#160/234 |
| Current Ratio | 4.37x | KR#361/2,436 Sec#67/234 |
| Performance | ||
| 1Y Return | -44.03% | KR#1,936/2,436 Sec#172/234 |
| 1M Return | 17.03% | KR#158/2,436 Sec#9/234 |
| From 52W High | -49.05% | KR#1,148/2,436 Sec#98/234 |
| 1Y MDD | -62.97% | KR#1,583/2,436 Sec#129/234 |
| Trading | ||
| Volume | 104,839 shares | KR#909/2,436 Sec#91/234 |
| Foreign Own. | 2.56% | KR—/2,436 Sec—/234 |
| Per Share | ||
| EPS | -468 KRW | KR—/2,436 Sec—/234 |
| BPS | 1,247 KRW | KR#2,227/2,436 Sec#198/234 |
Company Info
Eyegene, a bio venture founded in 2000 for proteomics and immunology research, established mRNA subsidiary Renaim and operates EyeGene Australia in 2021. The company's core focus is developing mRNA vaccines and AAV gene therapies, with gene and cell therapies at its center, having completed Phase 1/2a clinical trials for a COVID-19 preventive vaccine. It collaborates with five domestic and international companies on next-generation mRNA vaccine development and prioritizes technology acquisition through revenue-generating business and venture enterprise investments. Eyegene is headquartered in Uiwang-si, Gyeonggi-do.